ACVRL1 antikoerper, vgb antikoerper, alk1 antikoerper, zehn1109 antikoerper, hm:zehn1109 antikoerper, ACVRLK1 antikoerper, ALK-1 antikoerper, ALK1 antikoerper, HHT antikoerper, HHT2 antikoerper, ORW2 antikoerper, SKR3 antikoerper, TSR-I antikoerper, R-3 antikoerper, R3 antikoerper, SETHKIR antikoerper, AI115505 antikoerper, AI427544 antikoerper, Acvrlk1 antikoerper, Alk1 antikoerper, activin A receptor like type 1 antikoerper, activin A receptor type II-like 1 antikoerper, activin A receptor, type II-like 1 antikoerper, ACVRL1 antikoerper, acvrl1 antikoerper, Acvrl1 antikoerper
Hintergrund
ALK-1 or Activin receptor-like kinase-1 is a type I cell surface receptor for the TGF-beta (transforming growth factor-beta) super family of proteins. It is expressed predominantly in endothelial cells with moderate expression in smooth muscle cells, myofibroblast, hepatic stellate cells, chondrocytes, monocytes, myoblasts, macrophages and fibroblasts. ALK-1 plays a pivotal role in vascular remodelling and angiogenesis. More specifically its key function is in arterial/venous differentiation during embryonic vascular development. Mutations in ALK-1 gene (12q11-14) causes HHT2 (Hereditary Haemorrhagic Telangiectasia type 2), an autosomal dominant multisystem vascular dysplasia caused by a haploinsufficiency mechanism.